Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
第2相
完了
NCT00183820
| 対象疾患 | Testicular Cancer, Germ Cell Neoplasm |
|---|
| 相 | 第2相 |
|---|
| スポンサー | University of Southern California |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 30 名 |
|---|
| 介入（薬剤） | paclitaxel, gemcitabine, and oxaliplatin |
|---|
| 開始日 | 2004年11月 |
|---|
| 完了日 | 2015年12月 |
|---|
| 結果公開日 | 2026年7月1日 |
|---|
概要
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Tumor Response
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years · Participants
| Paclitaxel, Gemcitabine, and Oxaliplatin | 2 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 7 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 15 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 5 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。